Shots:
Orna to receive $150M up front & will be eligible to receive ~$3.5B in development, regulatory & sales milestones related to multiple vaccine and therapeutic programs along with royalties on any approved products that emerge from the collaboration. Merck will also invest $100M of equity in Orna’s completed series B financing round
Orna holds the rights for its oRNA-LNP technology platform & continues to advance other programs in areas incl. oncology & genetic disease
The collaboration will combine Merck’s expertise in nucleic acid biology, clinical development & manufacturing with Orna’s compelling circular RNA technology to develop multiple programs across infectious disease & oncology
Ref: Businesswire | Image: Merck
